Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications

NCT ID: NCT01318785

Last Updated: 2011-09-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Examination of therapeutical effects of different types of armsleeves in treating lymphatic diseases after breast cancer surgery during maintenance phase

1. thesis:

\- all types should be equal regarding volume reduction
2. thesis: armsleeves manufactured with microfibre yarn are expected to be

* better in wearing comfort and
* better in handling features.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. thesis:

* measuring of arm volume by "inverse water-volumetry" (see later)
* measuring of circumference cD
* measuring of circumference cG
* photodocumentation in 2 positions(during each round)
2. thesis

* questionaire for patients

* in the beginning
* after 1 week
* after 2 weeks (at the end of a wearing period)
* questionaire for study nurse (at the end of a wearing period)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Compression ArmsleevesType A

Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387

Group Type ACTIVE_COMPARATOR

Compression Armsleeves

Intervention Type OTHER

Type: Compression Class II (according to RAL)

The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.

Compression Armsleeves Type B

Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387

Group Type ACTIVE_COMPARATOR

Compression Armsleeves

Intervention Type OTHER

Type: Compression Class II (according to RAL)

The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Compression Armsleeves

Type: Compression Class II (according to RAL)

The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bauerfeind SoraLife Jobst Elvarex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women with a secondary arm-lymphedema for at least 3 months
* willingness to wear compression arm-sleeves for at least 12 hours per day
* maintenance phase, where no significant further reduction of arm-volume can be achieved
* lymphedema in stadium 1 or 2
* age: at least 18 years
* signed consent form by the patient
* sufficient knowledge in national language

Exclusion Criteria

* edema not completely reduced to "maintenance phase"
* immobilized patient
* acute deep vein thrombosis in arm
* directly after arm-vein-thrombosis
* acute arm erysipelas
* malignant edema
* existent lipedema
* arterial occlusion
* distinctive neuropathy in upper limbs
* neurinoma in upper limbs
* chronic pain after plastic surgery in upper limbs, shoulder or breast
* change in drug treatment, that can influence edema situation during the study
* pregnant women
* breast giving mothers
* not signed consent form
* participation in a second clinical trial
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KABEG Management

OTHER

Sponsor Role collaborator

Nij Smellinghe Hosptial

OTHER

Sponsor Role collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role collaborator

University Medicine Greifswald

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Klinik und Poliklinik für Hautkrankheiten der Universität Greifswald

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Jünger, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Klinik und Poliklinik für Hautkrankheiten der Universität Greifswald

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Landeskrankenhaus Wolfsberg

Wolfsberg, Carinthia, Austria

Site Status RECRUITING

Universitaire Ziekenhuizen

Leuven, , Belgium

Site Status RECRUITING

Klinik und Poliklinik für Hautkrankheiten, Sauerbruchstraße

Greifswald, Mecklenburg-Vorpommern, Germany

Site Status RECRUITING

Nij Smellinghe Hosptial

Drachten, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Germany Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Jünger, Prof. Dr.

Role: CONTACT

+493834-866770

Claudia Eggert, Study Nurse

Role: CONTACT

+493834-866770

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Walter Döller, MD

Role: primary

Maria Flour, MD

Role: primary

Michael Jünger, Prof. Dr.

Role: primary

+493834-866770

Claudia Eggert, Study Nurse

Role: backup

+493834-866770

Robert Damstra, MD

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

http://www.medizin.uni-greifswald.de/haut/

link to Greifswald dermatology

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Multicentrestudy "BF09-PH-01"

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.